CAR T-Cell Therapy for Non-Hodgkin Lymphoma

Video

The chief of oncology and hematology at University of Nebraska Medical Center discussed the use of CAR T-cell therapy in non-Hodgkin lymphoma.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Julie M. Vose, MD, MBA, about the use of CAR T-cell therapy in non-Hodgkin lymphoma (NHL). Vose is the Neumann M. and Mildred E. Harris Professor and chief of Oncology and Hematology in the Department of Internal Medicine at University of Nebraska Medical Center.

CAR T-cell therapies are being investigated for use in several subtypes of NHL in ongoing clinical trials. The therapies are currently indicated for use in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), as well as mantle cell lymphoma (MCL).

For example, trials are investigating CAR T-cell therapy in follicular lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. Additionally, other products beyond those FDA approved are being tested in DLBCL and MCL, Vose concludes.

Recent Videos
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Related Content
Novartis's CAR-T Tisagenlecleucel Continues to Show Efficacy for R/R Follicular Lymphoma in Long-Term Follow-Up

Novartis's CAR-T Tisagenlecleucel Continues to Show Efficacy for R/R Follicular Lymphoma in Long-Term Follow-Up

Jason M. Broderick
December 10th 2024
Article

The CAR-T, marketed as Kymriah, showed a 4-year overall survival rate of 79.3% and a median progression-free survival of 53.3 months.

Allogeneic CAR-NK Therapy TAK-007 Achieves Responses in R/R B-NHL

Allogeneic CAR-NK Therapy TAK-007 Achieves Responses in R/R B-NHL

Noah Stansfield
December 9th 2024
Article

With regard to safety, there were no dose-limiting toxicities, no cases of GvHD, and no cases of TAK-007-related ICANS.

Alexis Thompson, MD, MPH

bluebird bio’s Transfusion-Dependent β-Thalassemia Gene Therapy Beti-Cel Continues to Demonstrate Curative Potential in Long-Term Follow-Up Data

Noah Stansfield
December 9th 2024
Article

Protocol-defined transfusion independence (TI) was achieved by 52 of the 63 patients in long-term follow-up study LTF-303.

stem cell

Allogeneic Hematopoietic Stem Cell Transplantation Replicates Posititve Outcomes in Transfusion-Dependent Thalassemia

Matt Hoffman
December 8th 2024
Article

Allo-HSCT showed good 2-year survival data, with matched sibling donors showing superior outcomes to alternative donors.

Alaa Ali, MD, from the Lombardi Comprehensive Cancer Center, Georgetown University

Bendamustine Is an Effective Alternative to Fludarabine-Based Lymphodepletion in LBCL

Silas Inman
December 7th 2024
Article

In the wake of fludarabine shortages, lemphodepletion with bendamustine was found to be an effective alternative compared for patients with large B-cell lymphoma being treated with a CD19-directed CAR T-cell therapy.

Armin Ghobadi, MD, Division of Oncology, Washington University School of Medicine.

Tabelecleucel Efficacy Sustained in EBV-positive PTLD, as FDA Considers Application

Silas Inman
December 7th 2024
Article

With an FDA deadline pending in January, tabelecleucel remained safe and effective with longer follow-up for Epstein–Barr virus-associated post-transplant lymphoproliferative disease.

© 2024 MJH Life Sciences

All rights reserved.